AIDS Alert 2008-11-01

Medicare Part D has big impact on HIV treatment interruptions

Some of the concerns and predictions HIV/AIDS advocates made two years ago about the impact of Medicare Part Dthe prescription drug benefiton HIV antiretroviral treatment appear to be coming true. Read More

Medicare Part D has many pitfalls for HIV/AIDS patients

As if HIV clinics and physicians didn't have enough government paperwork and bureaucracy to worry about, the nearly three-year-old Medicare Part D prescription drug coverage offers a labyrinth of obstacles, pitfalls, and other problems in keeping HIV patients adherent to their antiretroviral treatment (ART). Read More

Starpharma optimistic new microbicide will beat odds

Jackie Fairley, BVSc, BSc, MBA, chief executive officer of Starpharma of Victoria, Australia, recently fielded some questions from AIDS Alert about the company's investigational microbicide, VivaGel.® Read More

Research shows protective effect of male circumcision

Just-presented research at the XVII International AIDS Conference in Mexico City indicates that adult male circumcision continues to reduce the risk of acquiring HIV through heterosexual intercourse for at least 3.5 years. Read More

FDA Notifications

On Sept. 24, 2008, FDA approved a generic formulation of Didanosine (ddI) Delayed Release Capsules, 125 mg, 200 mg, 250 mg, and 400 mg, manufactured by Aurobindo Pharma Limited, Hyberdad, India. Didanosine is a Nucleoside Reverse Transcriptase Inhibitors (NRTI), which helps keep HIV, the virus that causes AIDS, from reproducing, and is intended to be used with other anti-retroviral agents for the treatment of HIV-1 infection. Read More

CDC underscores HIV threat to Latinos

HIV remains a significant threat to the health of Latino communities in the United States, the Centers for Disease Control and Prevention warns. Read More

AIDS Alert Archives

November 1, 2008

View Archived Issues

Downloads